Mendeley出力
＜博士論文＞
原発性肺癌におけるペメトレキセドの感受性規定因子
| 作成者 | |
|---|---|
| 論文調査委員 | |
| 本文言語 | |
| 学位授与年度 | |
| 学位授与大学 | |
| 学位 | |
| 学位種別 | |
| アクセス権 | |
| 関連DOI | |
| 概要 | BACKGROUND:This study was designed to investigate potential molecules that predict chemosensitivity to pemetrexed (Alimta®) in surgically resected non-small cell lung cancer (NSCLC). MATERIALS AND METH...ODS:Chemosensitivity to ALM and other drugs was assessed by succinate dehydrogenase inhibition (SDI) test in 69 NSCLC samples (55 adenocarcinomas, and 14 squamous cell carcinomas). The mRNA expression levels of Alimta®-target enzymes [thymidylate synthase (TYMS); dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT)], Alimta®-metabolizing enzymes [γ-glutamyl hydrase (GGH) and folylpolyglutamate synthase] and an Alimta® transporter [reduce folate carrier (RFC)] were measured and examined for potential correlations to chemosensitivity. RESULTS:The squamous cell carcinoma samples showed higher TYMS expression and lower RFC expression than did the adenocarcinoma samples. In the adenocarcinoma sample analyses, GGH expression was inversely correlated to sensitivity. CONCLUSION:The histology-dependent differences in chemosensitivity to Alimta® may be attributed to the histology-dependent differences in TYMS and RFC expression. In adenocarcinomas, GGH potentially represents a marker for chemosensitivity to Alimta®.続きを見る |
本文ファイル
| ファイル | ファイルタイプ | サイズ | 閲覧回数 | 説明 |
|---|---|---|---|---|
med3133_abstract
|
101 KB | 166 | 要旨 | |
|
med3133_summary
|
101 KB | 106 | 要約 | |
|
med3133_review
|
168 KB | 117 | 審査結果要旨 |
詳細
| レコードID | |
|---|---|
| 査読有無 | |
| 権利関係 | |
| 関連PubMed ID | |
| 報告番号 | |
| 学位記番号 | |
| 授与日(学位/助成/特許) | |
| 受理日 | |
| 部局 | |
| 登録日 | 2018.05.30 |
| 更新日 | 2018.11.20 |